AG-CN2-0449-M0011 mgCHF 65.00
AG-CN2-0449-M0055 mgCHF 250.00
AG-CN2-0449-M01010 mgCHF 320.00
|Synonyms||Mycoporphyrin; NSC407313; Hypericum red|
|Merck Index||14: 4863|
|Source/Host Chemicals||Isolated from Hypericum perforatum.|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||Dark brown to black-red solid.|
|Solubility||Soluble in 100% ethanol, methanol or DMSO. In pure water, hypericin forms aggregates which are non-soluble and non-fluorescent.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
Keep cool and dry.
Keep under inert gas.
Protect from light.
Protect from moisture and oxygen.
Protect from light when in solution.
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- One of the principal active constituents of St. John's Wort (Hypericum perforatum).
- Hypericin is a photosensitive pigment/chromophore with bright red fluorescence emission (λmax: 594nm).
- Has a high triplet quantum yield and ability to produce considerable amounts of singlet oxygen and other ROS species when photoactivated.
- Antiviral, anticancer and antidepressant agent.
- Inactivates enveloped viruses (including HIV).
- This photosensitizing agent has shown to induce apoptosis and necrosis in cancer cells during photodynamic therapy.
- Selective inhibitor of protein kinase C (PKC). Has been shown to inhibit other kinases and targets such as EGFR-PTK, PI3K, CKII, MAPK and insulin receptor (IR).
- Necrosis-avid contrast agent investigated for use in non-invasively targeting necrotic tissues, based on to be defined components in the phospholipid bilayer.
- On the absorption spectrum of hypericin: N. Pace & G. Mackinney; JACS 61, 3594 (1939)
- Hypericin and its photodynamic action: N. Duran & P.S. Song; Photochem. Photobiol. 43, 677 (1986) (Review)
- Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity: I. Takahashi, et al.; BBRC 165, 1207 (1989)
- Virucidal Activity of Hypericin Against Enveloped and Non-enveloped DNA and RNA Viruses: J. Tang, et al.; Antivir. Res. 13, 313 (1990)
- Agents for treating human immunodeficiency virus infection: E.P. Acosta & C.V. Fletcher; Am. J. Hosp. Pharm. 51, 2251 (1994) (Review)
- Photosensitized inhibition of growth factor-regulated protein kinases by hypericin: P. Agostinis, et al.; Biochem. Pharmacol. 49, 1615 (1995)
- The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities: G. Lavie, et al.; Med. Res. Rev. 15, 111 (1995) (Review)
- Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells: R. Ebermann, et al.; J. Photochem. Photobiol. B. 36, 95 (1996) (Review)
- Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin: P. Agostinis, et al.; Adv. Enzyme Regul. 40, 157 (2000) (Review)
- St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties: J. Barnes, et al.; J. Pharm. Pharmacol. 53, 583 (2001) (Review)
- Hypericin in cancer treatment: more light on the way: P. Agostinis, et al.; Int. J. Biochem. Cell Biol. 34, 221 (2002) (Review)
- Hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules: P. Miskovsky; Curr. Drug Targets 3, 55 (2002) (Review)
- Mechanism of action of St John's wort in depression: what is known? V. Butterweck; CNS Drugs 17, 539 (2003) (Review)
- Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers: J. Piette, et al.; Biochem. Pharmacol. 66, 1651 (2003) (Review)
- Hypericin - the facts about a controversial agent: A. Kubin, et al.; Curr. Pharm. Des. 11, 233 (2005)
- The multifaceted photocytotoxic profile of hypericin: T.A. Theodossiou, et al.; Mol. Pharm. 6, 1775 (2009) (Review)
- Molecular response to hypericin-induced photodamage: B. Krammer & T. Verwanger; Curr. Med. Chem. 19, 793 (2012) (Review)
- Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging: B. Jiang, et al.; Theranostics 3, 667 (2013) (Review)